Lung cancer: Study finds potential new drug target

26 enero 2015

Targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat lung cancer, researchers report. Cancer cells undergo metabolic alterations to meet the increased energy demands that support their excess growth and survival. The Krebs cycle in the mitochondria of cells is used to supply both energy and building materials for cell growth. Two mitochondrial enzymes — pyruvate carboxylase (PC) and glutaminase replenish carbon to the Krebs cycle.